Solid Tumour Clinical Trial
Official title:
A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02648490 -
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
|
Phase 1 | |
Recruiting |
NCT01226407 -
Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
|
Phase 1 | |
Withdrawn |
NCT04891718 -
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
|
Early Phase 1 | |
Completed |
NCT01447732 -
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04958226 -
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT04121910 -
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
|
Phase 1 | |
Terminated |
NCT01219543 -
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
|
Phase 1 | |
Completed |
NCT01627990 -
Nivestimâ„¢ in Treatment of Malignant Diseases
|
N/A | |
Completed |
NCT01489826 -
A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
|
Phase 1 | |
Terminated |
NCT01516645 -
Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Unknown status |
NCT01046461 -
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
|
Phase 2 | |
Completed |
NCT02086721 -
Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT00467779 -
Study of GDC-0973/XL518 in Patients With Solid Tumors
|
Phase 1 |